Across TCGA pan-cancer cohorts, GJA9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GJA9 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GJA9 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GJA9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC and BRCA are the cancer types where GJA9 Mutation most reproducibly stratifies survival.